Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors MAR: organised manuscript, edited and reviewed information, contributed to patient consent form. AH: contributed to patient information and history, edited and reviewed document. SG: provided subspecialist/ophthalmology input for figure and discussion, contributed to and edited the manuscript. GK (senior author and guarantor): generated figures, reviewed mechanisms and contributed to editing and reference citation and discussion. None of the authors have any conflict of interest nor own any interests/stocks in the company making dupilumab.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
First published Reji MA, Haque A, Goyal S, et al. Dupilumab-induced ocular surface disease: a primer. BMJ Case Reports 2022;15:e249019.